AU4307396A - Kit for osteoporosis treatment cycle - Google Patents

Kit for osteoporosis treatment cycle Download PDF

Info

Publication number
AU4307396A
AU4307396A AU43073/96A AU4307396A AU4307396A AU 4307396 A AU4307396 A AU 4307396A AU 43073/96 A AU43073/96 A AU 43073/96A AU 4307396 A AU4307396 A AU 4307396A AU 4307396 A AU4307396 A AU 4307396A
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
tiludronic acid
calcium
kit
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43073/96A
Other languages
English (en)
Inventor
Martine Gazard
Jacques Girard
Olivier Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU4307396A publication Critical patent/AU4307396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU43073/96A 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle Abandoned AU4307396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9414630A FR2727629A1 (fr) 1994-12-06 1994-12-06 Trousse pour cycle de traitement de l'osteoporose
FR9414630 1994-12-06
PCT/FR1995/001596 WO1996017616A1 (fr) 1994-12-06 1995-12-05 Trousse pour cycle de traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
AU4307396A true AU4307396A (en) 1996-06-26

Family

ID=9469504

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43073/96A Abandoned AU4307396A (en) 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle

Country Status (20)

Country Link
EP (1) EP0797444A1 (enExample)
JP (1) JPH10509729A (enExample)
KR (1) KR980700083A (enExample)
CN (1) CN1168634A (enExample)
AR (1) AR002946A1 (enExample)
AU (1) AU4307396A (enExample)
BR (1) BR9509961A (enExample)
CA (1) CA2207028A1 (enExample)
CZ (1) CZ175397A3 (enExample)
FI (1) FI972383A7 (enExample)
FR (1) FR2727629A1 (enExample)
HU (1) HUT77382A (enExample)
IL (1) IL116168A0 (enExample)
MA (1) MA23737A1 (enExample)
NO (1) NO972558L (enExample)
PL (1) PL320564A1 (enExample)
SK (1) SK68597A3 (enExample)
TR (1) TR199501530A1 (enExample)
WO (1) WO1996017616A1 (enExample)
ZA (1) ZA9510184B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
ES2530791T3 (es) * 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381296B1 (en) * 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
TR199501530A1 (tr) 1996-10-21
MX9704105A (es) 1997-09-30
CA2207028A1 (en) 1996-06-13
NO972558D0 (no) 1997-06-05
AR002946A1 (es) 1998-05-27
FI972383L (fi) 1997-06-05
MA23737A1 (fr) 1996-07-01
KR980700083A (ko) 1998-03-30
PL320564A1 (en) 1997-10-13
CN1168634A (zh) 1997-12-24
ZA9510184B (en) 1996-06-11
IL116168A0 (en) 1996-01-31
FR2727629B1 (enExample) 1997-02-28
JPH10509729A (ja) 1998-09-22
HUT77382A (hu) 1998-04-28
SK68597A3 (en) 1997-11-05
BR9509961A (pt) 1997-11-25
FR2727629A1 (fr) 1996-06-07
CZ175397A3 (en) 1997-10-15
FI972383A0 (fi) 1997-06-05
NO972558L (no) 1997-08-05
WO1996017616A1 (fr) 1996-06-13
EP0797444A1 (fr) 1997-10-01
FI972383A7 (fi) 1997-06-05

Similar Documents

Publication Publication Date Title
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US4861590A (en) Sustained release fluoride and calcium composition
CA2454200A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
JP2014205711A (ja) ビタミンｄ誘導体の前用量投与によってアレンドロネート等のビスフォスフォネートの生体利用効率を高める方法
DE69837450T2 (de) Alendronate zur Behandlung von Osteoporose
US20050214388A1 (en) Multivitamin formulations containing controlled-release magnesium
KR100263284B1 (ko) 활성성분으로서의 디클로로메틸렌디포스폰산을 함유하는 생체 이용률이 개선된 정제
US4859467A (en) Sustained release fluoride composition
US5013728A (en) Composition for treating osteoporosis and hormonal imbalance
CZ219798A3 (cs) Prostředek pro prevenci a léčbu osteoporézy
CA2671727C (en) A composition containing a bisphosphonic acid in combination with vitamin d
EP0521057A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL USES OF THESE COMPOSITIONS.
EP2097137B1 (en) Compositions comprising strontium and uses thereof in the treatment or prevention of gingivitis, periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal diseases.
US5286490A (en) Transdermal fluoride medication
CA2207028A1 (en) Kit for osteoporosis treatment cycle
CA2219354A1 (en) Prevention of tooth loss by the administration of alendronate or its salts
MXPA97004105A (en) Set for use in a therapeutic treatment cycle of osteoporo
US4517309A (en) Method for the treatment of calcifying pancreatitis
HU211084B (en) Process for producing oral pharmaceutical composition of bone strengthening activity
EP0268868A2 (en) Pharmaceutical compositions for the treatment of gastro-intestinal diseases
HK1018405A (en) Composition containing diosgenin
HK1182623A (en) A composition containing a bisphosphonic acid in combination with vitamin d
JPS58185519A (ja) 抗高燐血症剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted